Vitamin D Optimal Levels: How to Test, Interpret, and Correct Deficiency

Vitamin D Is a Steroid Hormone, Not Just a Vitamin

The name "vitamin D" is a historical misnomer. Unlike true vitamins — organic compounds that must be obtained from food because the body cannot synthesize them — vitamin D is produced by the human body when skin is exposed to ultraviolet B radiation. More precisely, vitamin D functions as a steroid hormone after conversion to its biologically active form, 1,25-dihydroxyvitamin D (calcitriol). The vitamin D receptor (VDR) is found in virtually every tissue in the human body, from immune cells and brain neurons to cardiac muscle, pancreatic beta cells, and adipose tissue. Genome-wide analyses have identified over 1,000 genes regulated by vitamin D signaling — a scope of genomic influence rivaled by very few molecules in human biology.

This hormonal status means that vitamin D deficiency is not merely a bone health problem. Insufficient vitamin D impairs immune surveillance, increases inflammatory tone, disrupts insulin secretion, reduces muscle protein synthesis, impairs cognitive function, and dysregulates the renin-angiotensin system (blood pressure regulation). Understanding vitamin D as a broad-spectrum hormonal regulator explains why its insufficiency is associated with such a wide range of health conditions in observational studies.

Testing: Why 25(OH)D Is the Right Measure

Two forms of vitamin D circulate in blood: 25-hydroxyvitamin D (25(OH)D, calcidiol) and 1,25-dihydroxyvitamin D (1,25(OH)2D, calcitriol). Physicians commonly request 1,25(OH)2D thinking they are measuring the "active form" — but this is incorrect for assessing vitamin D status. 1,25(OH)2D is tightly regulated at the kidney and reflects current metabolic demand, not vitamin D stores. Its level can be normal or even elevated in individuals with severe deficiency because the body maximizes calcitriol production when stores are low. 25(OH)D is the storage form, has a half-life of 2 to 3 weeks, and accurately reflects total body vitamin D stores from both sun exposure and supplementation. Always request 25(OH)D, not 1,25(OH)2D, when assessing vitamin D status.

Testing methodology matters more than most patients or physicians realise. Two main assay types are in common use: immunoassay (competitive binding, commonly automated on clinical laboratory analyzers) and liquid chromatography-tandem mass spectrometry (LC-MS/MS, considered the reference method). Immunoassays are faster and cheaper but have significant inter-laboratory variability — results can differ by 20 to 30 percent between laboratories using different immunoassay platforms. LC-MS/MS provides superior precision but is more expensive and used primarily by reference laboratories. For tracking an individual's vitamin D status over time, using the same laboratory and the same assay platform is important to ensure changes reflect genuine physiological changes rather than inter-laboratory measurement variation. The Vitamin D Standardization Program (VDSP), established to harmonize vitamin D testing across laboratories, has improved but not eliminated this variability. Retesting 8 to 12 weeks after starting or adjusting supplementation (allowing time for the 2–3 week half-life of 25(OH)D to reach a new steady state) is sufficient to assess the response to a supplementation change.

Interpreting Your Results: A Framework

The reference ranges for 25(OH)D are among the most contested in clinical medicine, with major bodies using substantially different thresholds. This is not a minor discrepancy — the Institute of Medicine (now the National Academy of Medicine) defines sufficiency at 20 ng/mL, while the Endocrine Society places it at 40 to 60 ng/mL, and research-oriented groups like Grassroots Health recommend 60 to 80 ng/mL based on epidemiological data. The disagreement reflects genuinely different questions: the IOM threshold is calibrated to prevent classical vitamin D deficiency disease (rickets, osteomalacia) in the general population; the Endocrine Society threshold is based on evidence for broader biological functions including immune regulation and cardiovascular effects. Practically, a level that is "sufficient" to prevent rickets is not necessarily the level that optimises immune function, cancer risk reduction, or cardiometabolic health. The table below summarises the key reference ranges:

For clinical practice, the working target is the Endocrine Society's 40–60 ng/mL range, not the IOM's 20 ng/mL sufficiency minimum — the distinction matters because supplementation dosing is calibrated to that target. A result of 22 ng/mL is technically "sufficient" by IOM criteria but would warrant supplementation under Endocrine Society guidance. The gap between tested and optimal is the norm, not the exception: typical North American diets provide only 200–400 IU of vitamin D per day from food (fatty fish, fortified dairy, eggs), while reaching and maintaining the 40–60 ng/mL range generally requires 1,000–4,000 IU/day in combination with available sun exposure. Several populations face systematically deeper deficits and benefit most from proactive testing and supplementation: people with darker skin tones (melanin reduces UVB-mediated synthesis by up to 99 percent at high concentrations), those with limited sun exposure (indoor workers, northern latitudes, habitual sunscreen users), individuals with obesity (adipose tissue sequesters vitamin D, reducing circulating 25(OH)D), older adults (skin thins with age, reducing synthesis efficiency), and those with malabsorption conditions (Crohn's disease, celiac disease, bariatric surgery) that impair fat-soluble vitamin uptake.

The VITAL Trial: What the Evidence Shows for Supplementation

The VITAL trial (Vitamin D and Omega-3 Trial), led by JoAnn Manson at Harvard and published in the New England Journal of Medicine in 2019, was the largest and most rigorous randomized controlled trial of vitamin D supplementation to date. It enrolled 25,871 adults (men ≥50, women ≥55) with no prior cardiovascular disease or cancer, randomizing them to vitamin D3 2,000 IU/day or placebo, with an average follow-up of 5.3 years.

The primary results were largely null: vitamin D3 supplementation did not significantly reduce the primary endpoints of major cardiovascular events or invasive cancer incidence in the overall population. However, the secondary and subgroup analyses were substantially more encouraging. Cancer mortality — the risk of dying from cancer — was reduced by 25 percent overall (statistically significant). In participants who were not overweight (BMI under 25), cancer incidence was also significantly reduced by approximately 24 percent. In participants who had taken vitamin D for more than 2 years, cancer mortality reductions were 42 percent compared to placebo. The interpretation is that vitamin D supplementation may primarily affect cancer progression and survival rather than initial tumor development, and that the benefit is more pronounced in normal-weight individuals (where vitamin D distribution into fat tissue is not diluting circulating levels).

Vitamin K2: The Essential Co-Factor

Vitamin D supplementation increases calcium absorption from the gut. This calcium needs to be directed to bone and away from soft tissues (arteries, kidneys) where calcium deposition contributes to calcification and cardiovascular disease. Vitamin K2 (specifically the MK-7 form, menaquinone-7) activates two key proteins that direct calcium appropriately: osteocalcin (directs calcium into bone matrix) and matrix Gla protein (MGP, inhibits calcium deposition in arterial walls). Without adequate K2, elevated calcium from vitamin D supplementation may theoretically increase soft tissue calcification risk. While the clinical evidence for this interaction is still developing, most integrative medicine practitioners recommend 100 to 200 mcg/day of K2-MK7 when supplementing with more than 2,000 IU/day of vitamin D3.

Magnesium is equally important: it is required as a cofactor for the enzymatic conversion of vitamin D to its active form (25-hydroxylation in the liver, then 1-alpha-hydroxylation in the kidney). Approximately 500 mg/day of dietary magnesium is needed for optimal vitamin D activation — deficiency in magnesium (common in Western diets) can impair the conversion of supplemented vitamin D to its active calcitriol form.

Sun Exposure vs Supplementation

Sun exposure and supplementation address the same deficit through different means and carry distinct advantages. Cutaneous vitamin D synthesis begins when UVB radiation (wavelength 290–315nm) converts 7-dehydrocholesterol in the skin to pre-vitamin D3, which is thermally converted to vitamin D3 and enters the circulation. This process is self-limiting — prolonged UV exposure causes pre-vitamin D3 to be photodegraded into biologically inactive compounds (lumisterol, tachysterol), preventing toxicity from sun exposure alone. The amount synthesised depends critically on skin type (fair skin synthesises more efficiently), time of day (UVB is only available when the solar zenith angle is less than 55 degrees — typically 10am to 3pm in summer at northern temperate latitudes), latitude (above 35°N in winter, UVB is absent regardless of time outdoors), season, and skin surface area exposed. At latitude 51°N (London), meaningful vitamin D synthesis is only possible from approximately April to October. Sunscreen with SPF 30 reduces synthesis by 95 to 99 percent.

Beyond vitamin D, sun exposure provides benefits that supplements do not replicate: circadian rhythm entrainment (morning sunlight via melanopsin activation in the eye sets the master clock), nitric oxide release from nitrite stores in skin (independent of vitamin D, with cardiovascular effects), and immune modulation through direct UV effects on dendritic cells in the skin. These pleiotropic effects of sunlight make moderate unprotected sun exposure during peak UVB hours a meaningful health intervention distinct from vitamin D supplementation. For population-wide sufficiency year-round regardless of geography, season, skin type, and lifestyle, supplementation remains the most reliable and controllable approach.

A Practical Vitamin D Protocol

A complete evidence-based approach integrates testing, supplementation, and co-factors. Step 1: test baseline 25(OH)D in late winter (when levels are at their seasonal nadir) to get the most clinically meaningful starting point. Step 2: determine supplementation dose based on baseline — for deficiency (below 20 ng/mL), 4,000–6,000 IU/day of vitamin D3 for 8–12 weeks, then retest and transition to maintenance. For insufficiency (20–40 ng/mL), 2,000–4,000 IU/day. For maintenance of existing sufficiency, 1,000–2,000 IU/day depending on body weight and ongoing sun exposure. Step 3: take vitamin D3 (not D2) with the largest fat-containing meal of the day for maximal absorption. Step 4: pair with vitamin K2-MK7 (100–200 mcg/day) and ensure adequate dietary magnesium or supplement with magnesium glycinate (300–400 mg/day). Step 5: retest after 8–12 weeks to confirm you have reached the 40–60 ng/mL target range, and adjust dose accordingly. Annual retesting in late winter maintains oversight of status across seasons.

At doses above 4,000 IU/day, monitoring calcium alongside vitamin D becomes important for detecting hypercalcemia early — though blood calcium alone is not the most sensitive indicator. Parathyroid hormone (PTH) actively compensates to maintain serum calcium within normal range even as vitamin D rises, meaning blood calcium can remain normal until the compensatory mechanism is overwhelmed. A more sensitive early indicator is 24-hour urine calcium (ideally below 250 mg/day in women, 300 mg/day in men); clinical symptoms — fatigue, increased thirst, frequent urination, constipation, or muscle weakness — warrant immediate retesting. The risk window for genuine hypercalcemia toxicity is generally associated with prolonged 25(OH)D levels above 100 ng/mL, not with the 40–60 ng/mL target range this protocol aims for. Once the target range is confirmed by retesting at 8–12 weeks, ongoing oversight is straightforward: annual testing in autumn (for those at northern latitudes, after summer synthesis has peaked and before winter depletion sets in) is sufficient to ensure maintenance doses are keeping levels on track. The goal is a stable, verified number — not a perpetual high-dose regimen.